Last Updated: May 2, 2026

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Dapagliflozin And Metformin Hydrochloride, and when can generic versions of Dapagliflozin And Metformin Hydrochloride launch?

Dapagliflozin And Metformin Hydrochloride is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma, Cipla, Cipla Ltd, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, MSN, Sun Pharm, and Teva Pharms Usa Inc. and is included in ten NDAs.

The generic ingredient in DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE is dapagliflozin; metformin hydrochloride. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dapagliflozin And Metformin Hydrochloride

A generic version of DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE was approved as dapagliflozin; metformin hydrochloride by ALKEM LABS LTD on April 6^th, 2026.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
What are the global sales for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
What is Average Wholesale Price for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?

Summary for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

US Patents:	0
Applicants:	10
NDAs:	10

US Patents and Regulatory Information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa Inc	DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211583-001	Apr 6, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211479-003	Apr 6, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Teva Pharms Usa Inc	DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211583-003	Apr 6, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sun Pharm	DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	dapagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211491-001	Apr 6, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.